Acadia Pharmaceuticals Share Price (NASDAQ: ACAD)

$25.74

▲

0.95

(3.83%)

Last updated on August 23, 2025 at 1:29 AM IST

$₹

Check the interactive Acadia Pharmaceuticals Stock chart to analyse performance

Acadia Pharmaceuticals stock performance

as on August 23, 2025 at 1:29 AM IST

Today's Low:$24.95
Today's High:$25.80
$25.74
3.07%
Downside
Day's Volatility :3.29%
Upside
0.23%
52 Weeks Low:$13.40
52 Weeks High:$25.88
$25.74
47.94%
Downside
52 Weeks Volatility :48.21%
Upside
0.52%

Acadia Pharmaceuticals Stock Returns

Period	Acadia Pharmaceuticals Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	11.72%	5.0%	0.0%
6 Months	27.26%	-6.4%	0.0%
1 Year	55.52%	-11.5%	0.0%
3 Years	44.63%	4.5%	-7.7%

Acadia Pharmaceuticals Inc. Key Stats

Check Acadia Pharmaceuticals key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$24.79
Open	$24.95
Today's High	$25.8
Today's Low	$24.95
Market Capitalization	$4.2B
Today's Volume	$999.0K
52 Week High	$25.875
52 Week Low	$13.4
Revenue TTM	$1.0B
EBITDA	$104.0M
Earnings Per Share (EPS)	$1.33
PE Ratio	18.64
Profit Margin	21.8%
Quarterly Earnings Growth YOY	-0.21%
Return On Equity TTM	33.18%

Stock Returns calculator for Acadia Pharmaceuticals Stock including INR - Dollar returns

The Acadia Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Acadia Pharmaceuticals investment value today

Current value as on today

₹1,65,762

Returns

₹65,762

(+65.76%)

Returns from Acadia Pharmaceuticals Stock

₹61,481 (+61.48%)

Dollar Returns*

₹4,281 (+4.28%)

Indian investors sentiment towards Acadia Pharmaceuticals Stock

100%

Period: Jul 23, 2025 to Aug 22, 2025. Change in 30 Days versus previous period

Search interest for Acadia Pharmaceuticals Stock from India on INDmoney has increased by 100% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Acadia Pharmaceuticals Inc.

Name
Holdings %
Name
Holdings %
Baker Bros Advisors LP
25.41%
BlackRock Inc
12.66%
Vanguard Group Inc
9.05%
RTW INVESTMENTS, LLC
5.33%
State Street Corp
4.15%
Morgan Stanley - Brokerage Accounts
2.77%

Analyst Recommendation on Acadia Pharmaceuticals Stock

Rating

Trend

Buy

73%Buy

23%Hold

3%Sell

Based on 26 Wall street analysts offering stock ratings for Acadia Pharmaceuticals(by analysts ranked 0 to 5 stars)

Acadia Pharmaceuticals Share Price Target

What analysts predicted

Upside of 16.35%

Target:

$29.95

Current:

$25.74

Acadia Pharmaceuticals share price target is $29.95, a slight Upside of 16.35% compared to current price of $25.74 as per analysts' prediction.

Acadia Pharmaceuticals Stock Insights

Price Movement
In the last 1 month, ACAD stock has moved up by 9.8%
Increasing Revenue
Revenue is up for the last 2 quarters, 244.31M → 264.56M (in $), with an average increase of 7.7% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, 18.98M → 26.66M (in $), with an average increase of 28.8% per quarter
ACAD vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 68.3% return, outperforming this stock by 10.2%
ACAD vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 114.2% return, outperforming this stock by 66.2%
Price to Sales
ForACAD every $1 of sales, investors are willing to pay $4.1, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $24.6 for every $1 of sales.

Acadia Pharmaceuticals Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$339.1M	↑ 51.5%
Net Income	$-235.3M	↓ 4.05%
Net Profit Margin	-69.38%	↑ 40.18%

	FY20	Y/Y Change
Revenue	$441.8M	↑ 30.28%
Net Income	$-281.6M	↑ 19.69%
Net Profit Margin	-63.74%	↑ 5.64%

	FY21	Y/Y Change
Revenue	$484.1M	↑ 9.6%
Net Income	$-167.9M	↓ 40.38%
Net Profit Margin	-34.67%	↑ 29.07%

	FY22	Y/Y Change
Revenue	$517.2M	↑ 6.83%
Net Income	$-216.0M	↑ 28.66%
Net Profit Margin	-41.76%	↓ 7.09%

	FY23	Y/Y Change
Revenue	$726.4M	↑ 40.45%
Net Income	$-61.3M	↓ 71.62%
Net Profit Margin	-8.44%	↑ 33.32%

	FY24	Y/Y Change
Revenue	$957.8M	↑ 31.85%
Net Income	$226.5M	↓ 469.5%
Net Profit Margin	23.64%	↑ 32.08%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$205.8M	↓ 10.91%
Net Income	$16.6M	↓ 63.85%
Net Profit Margin	8.04%	↓ 11.78%

	Q2 FY24	Q/Q Change
Revenue	$242.0M	↑ 17.55%
Net Income	$33.4M	↑ 101.69%
Net Profit Margin	13.8%	↑ 5.76%

	Q3 FY24	Q/Q Change
Revenue	$250.4M	↑ 3.49%
Net Income	$32.8M	↓ 1.87%
Net Profit Margin	13.09%	↓ 0.71%

	Q4 FY24	Q/Q Change
Revenue	$259.6M	↑ 3.67%
Net Income	$143.7M	↑ 338.71%
Net Profit Margin	55.37%	↑ 42.28%

	Q1 FY25	Q/Q Change
Revenue	$244.3M	↓ 5.89%
Net Income	$19.0M	↓ 86.79%
Net Profit Margin	7.77%	↓ 47.6%

	Q2 FY25	Q/Q Change
Revenue	$264.6M	↑ 8.29%
Net Income	$26.7M	↑ 40.44%
Net Profit Margin	10.08%	↑ 2.31%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$319.5M	↑ 55.48%

	FY20	Y/Y Change
Profit	$421.2M	↑ 31.84%

	FY21	Y/Y Change
Profit	$465.0M	↑ 10.4%

	FY22	Y/Y Change
Profit	$507.1M	↑ 9.05%

	FY23	Y/Y Change
Profit	$680.7M	↑ 34.24%

	FY24	Y/Y Change
Profit	$876.0M	↑ 28.68%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$182.9M	↓ 14.2%

	Q2 FY24	Q/Q Change
Profit	$223.7M	↑ 22.34%

	Q3 FY24	Q/Q Change
Profit	$231.5M	↑ 3.49%

	Q4 FY24	Q/Q Change
Profit	$237.8M	↑ 2.7%

	Q1 FY25	Q/Q Change
Profit	$223.9M	↓ 5.83%

	Q2 FY25	Q/Q Change
Profit	$243.8M	↑ 8.89%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-151.1M	↓ 9.76%
Investing Cash Flow	$-165.8M	↑ 131.97%
Financing Cash Flow	$371.8M	↑ 21.26%

	FY20	Y/Y Change
Operating Cash Flow	$-136.2M	↓ 9.9%
Investing Cash Flow	$192.5M	↓ 216.08%
Financing Cash Flow	$81.0M	↓ 78.22%

	FY21	Y/Y Change
Operating Cash Flow	$-125.7M	↓ 7.72%
Investing Cash Flow	$-71.1M	↓ 136.93%
Financing Cash Flow	$18.2M	↓ 77.58%

	FY22	Y/Y Change
Operating Cash Flow	$-114.0M	↓ 9.25%
Investing Cash Flow	$73.2M	↓ 203.01%
Financing Cash Flow	$8.2M	↓ 54.86%

	FY23	Y/Y Change
Operating Cash Flow	$16.7M	↓ 114.65%
Investing Cash Flow	$32.0M	↓ 56.31%
Financing Cash Flow	$25.1M	↑ 206.49%

	FY24	Y/Y Change
Operating Cash Flow	$157.7M	↑ 844.31%
Investing Cash Flow	$-30.5M	↓ 195.44%
Financing Cash Flow	$6.8M	↓ 72.76%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$29.1M	↓ 65.95%
Investing Cash Flow	$-14.0M	↑ 3945.82%
Financing Cash Flow	$1.0M	↓ 80.81%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$25.0M	↓ 13.98%
Investing Cash Flow	$-56.2M	↑ 300.26%
Financing Cash Flow	$3.6M	↑ 241.8%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$63.2M	↑ 152.85%
Investing Cash Flow	$-82.5M	↑ 46.74%
Financing Cash Flow	$268.0K	↓ 92.48%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$40.4M	↓ 36.15%
Investing Cash Flow	$122.2M	↓ 248.14%
Financing Cash Flow	$2.0M	↑ 634.7%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$20.3M	↓ 49.67%
Investing Cash Flow	$-124.0M	↓ 201.55%
Financing Cash Flow	$1.8M	↓ 6.65%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$64.0M	↑ 214.7%
Investing Cash Flow	$-43.3M	↓ 65.1%
Financing Cash Flow	$16.0M	↑ 768.12%

Acadia Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Acadia Pharmaceuticals is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Acadia Pharmaceuticals Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Acadia Pharmaceuticals Inc.	7.55%	27.26%	55.52%	44.63%	-34.76%
Regeneron Pharmaceuticals, Inc.	4.5%	-16.14%	-50.12%	-0.77%	0.56%
Beone Medicines Ltd	6.48%	21.45%	61.97%	78.16%	32.24%
Vertex Pharmaceuticals Incorporated	-16.69%	-17.5%	-17.43%	36.53%	48.58%
Alnylam Pharmaceuticals, Inc.	43.34%	87.51%	71.21%	111.21%	254.29%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Acadia Pharmaceuticals Inc.	18.64	18.64	-0.42	0.54	0.33	0.05	NA	4.88
Regeneron Pharmaceuticals, Inc.	14.9	14.9	1.21	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.29	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	28.01	28.01	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Acadia Pharmaceuticals Inc.	Buy	$4.2B	-34.76%	18.64	21.8%
Regeneron Pharmaceuticals, Inc.	Buy	$62.6B	0.56%	14.9	31.37%
Beone Medicines Ltd	NA	$37.6B	32.24%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$101.1B	48.58%	28.01	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$60.1B	254.29%	NA	-12.96%

About Acadia Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer's disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage. The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Organization	Acadia Pharmaceuticals
Employees	653
CEO	Ms. Catherine E. Owen Adams
Industry	Health Technology

Key Management of Acadia Pharmaceuticals Inc.

Name	Title
Ms. Catherine E. Owen Adams	CEO & Director
Mr. Mark C. Schneyer	Executive VP & CFO
Ms. Jennifer J. Rhodes J.D.	Executive VP, Chief Legal Officer & Secretary
Mr. Stephen R. Davis J.D.	Consultant
Dr. Elizabeth H. Z. Thompson Ph.D.	Executive VP and Head of Research & Development
Mr. Thomas Andrew Garner	Executive VP & Chief Commercial Officer
Mr. Scott Cenci	Senior VP, Chief Information & Data Officer
Mr. Rob Ackles	Senior VP & Chief People Officer
Mr. James K. Kihara	Senior Vice President of Finance
Dr. Kevin R. Oliver Ph.D.	Senior VP & Chief Business Officer

Important FAQs about investing in ACAD Stock from India :

What is Acadia Pharmaceuticals share price today?

Acadia Pharmaceuticals share price today is $25.74 as on August 23, 2025 at 1:29 AM IST at the close of the market. Acadia Pharmaceuticals share today touched a day high of $25.80 and a low of $24.95.

What is the 52 week high and 52 week low for Acadia Pharmaceuticals share?

Acadia Pharmaceuticals share touched a 52 week high of $25.88 and a 52 week low of $13.40. Acadia Pharmaceuticals stock price today i.e. August 23, 2025 at 1:29 AM IST is closed at $25.74, lower by 0.52% versus the 52 week high.

How to invest in Acadia Pharmaceuticals Stock (ACAD) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Acadia Pharmaceuticals on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Acadia Pharmaceuticals Shares that will get you 0.0583 shares as per Acadia Pharmaceuticals share price of $25.74 per share as on August 23, 2025 at 1:29 AM IST.

What is the minimum amount required to buy Acadia Pharmaceuticals Stock (ACAD) from India?

Indian investors can start investing in Acadia Pharmaceuticals (ACAD) shares with as little as ₹87.521 or $1 (as of August 23, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹875.21 in Acadia Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on August 23, 2025). Based on Acadia Pharmaceuticals share’s latest price of $25.74 as on August 23, 2025 at 1:29 AM IST, you will get 0.3885 shares of Acadia Pharmaceuticals. Learn more about fractional shares .

What are the returns that Acadia Pharmaceuticals has given to Indian investors in the last 5 years?

Acadia Pharmaceuticals stock has given -34.76% share price returns and 18.0% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?